Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Multivalent vaccines demonstrate immunogenicity and protect against Coxiella burnetii aerosol challenge

ABSTRACT: Multivalent vaccines demonstrate immunogenicity and protect against Coxiella burnetii aerosol challenge

PROVIDER: PRJNA953973 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Multivalent vaccines demonstrate immunogenicity and protect against Coxiella burnetii aerosol challenge

Project description:C57BL/6 mice were immunized with Coxiella burnetii vaccine Q-VAX (Seqirus) and monitored for up to 83 days post immunization. Two different routes of immunization were observed - subcutaneous and intramuscular. Subcutaneously immunized animals were boosted on day 67.

2023-04-11 | GSE229293 | GEO

Aerosol

Project description:Aerosol Genome sequencing

| PRJNA1013017 | ENA

aerosol metagenome

Project description:aerosol metagenome Raw sequence reads

| PRJNA648253 | ENA

aerosol metagenome

Project description:aerosol metagenome Raw sequence reads

| PRJNA839856 | ENA

aerosol metagenome

Project description:aerosol metagenome Raw sequence reads

| PRJNA645037 | ENA

aerosol metagenome

Project description:aerosol metagenome Raw sequence reads

| PRJNA420187 | ENA

aerosol metagenome

Project description:Microbial community structure in the aerosol samples

| PRJDB4590 | ENA

Adjuvant Pressurized Intraperitoneal Aerosol Chemotherapy to Prevent Colorectal Peritoneal Metastases (ProphyPIPAC)

Project description:The objective of this clinical trial is to demonstrate the feasibility and safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the prevention of peritoneal metastases after curative-intent surgery for high-risk colorectal cancer.

| 110015 | ecrin-mdr-crc

Seawater and Aerosol Metagenome

Project description:Seawater and Aerosol Metagenome Metagenome

| PRJNA541048 | ENA

Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth.

Project description:Human cytomegalovirus (HCMV) remains the most common congenital infection and infectious complication in immunocompromised patients. The most successful HCMV vaccine to date, an HCMV glycoprotein B (gB) subunit vaccine adjuvanted with MF59, achieved 50% efficacy against primary HCMV infection. A previous study demonstrated that gB/MF59 vaccinees were less frequently infected with HCMV gB genotype strains most similar to the vaccine strain than strains encoding genetically distinct gB genotypes, suggesting strain-specific immunity accounted for the limited efficacy. To determine whether vaccination with multiple HCMV gB genotypes could increase the breadth of anti-HCMV gB humoral and cellular responses, we immunized 18 female rabbits with monovalent (gB-1), bivalent (gB-1+gB-3), or pentavalent (gB-1+gB-2+gB-3+gB-4+gB-5) gB lipid nanoparticle-encapsulated nucleoside-modified RNA (mRNA-LNP) vaccines. The multivalent vaccine groups did not demonstrate a higher magnitude or breadth of the IgG response to the gB ectodomain or cell-associated gB compared to that of the monovalent vaccine. Also, the multivalent vaccines did not show an increase in the breadth of neutralization activity and antibody-dependent cellular phagocytosis against HCMV strains encoding distinct gB genotypes. Interestingly, peripheral blood mononuclear cell-derived gB-2-specific T-cell responses elicited by multivalent vaccines were of a higher magnitude compared to that of monovalent vaccinated animals against a vaccine-mismatched gB genotype at peak immunogenicity. Yet, no statistical differences were observed in T cell response against gB-3 and gB-5 variable regions among the three vaccine groups. Our data suggests that the inclusion of multivalent gB antigens is not an effective strategy to increase the breadth of anti-HCMV gB antibody and T cell responses. Understanding how to increase the HCMV vaccine protection breadth will be essential to improve the vaccine efficacy.

| S-EPMC10879498 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data